From June 24 to 26, 2025, the 23rd World Pharmaceutical Raw Materials China Exhibition & 18th World Pharmaceutical Machinery, Packaging Equipment and Materials China Exhibition (CPHI & PMEC China 2025) will be grandly held at the Shanghai New International Expo Center (Pudong). To promote intelligent transformation in the pharmaceutical raw materials field and create an efficient and collaborative new ecosystem for the pharmaceutical industry, the Pharmaceutical Raw Materials Intelligent Manufacturing Industry Forum will also be held concurrently.
In the current wave of intelligent manufacturing sweeping the globe, pharmaceutical raw material production is facing unprecedented opportunities for technological innovation. On June 24, the forum will gather elites from industry, academia, and research to deeply discuss topics such as the current status and trends of China's API industry, the construction and application of multidimensional analysis technology systems for new molecular drug R&D, exploring the integration of technological innovation and industrial application, and unlocking the unlimited potential of pharmaceutical raw materials intelligent manufacturing. Industry partners are sincerely invited to attend, jointly discuss the new future of pharmaceutical raw materials intelligent manufacturing, and plan a new blueprint for high-quality industry development!
Register now to receive free tickets worth hundreds of yuan!
(Deadline: June 19, 2025, 24:00)
Attendees have the chance to receive free meal coupons — limited to 10, first come first served!
Chen Ying
Director of Marketing and Academic Affairs / Senior Industry Analyst
China National Pharmaceutical Industry Information Center
Speech Time: 13:40–14:10
Topic: "Current Status and Trends in China's Active Pharmaceutical Ingredient (API) Industry"
About the Speaker: Ms. Chen Ying has many years of experience in pharmaceutical informatization product marketing, focusing on big data research in the pharmaceutical industry, customized pharmaceutical information product innovation, and cutting-edge industry research. She has deep insight and understanding of industry trends and market demand.
About the Organization: The China Pharmaceutical Industry Information Center is a professional institution engaged in biopharmaceutical information research, consulting, and services nationwide. With a unique brand in value-added information services in the biopharmaceutical field, it adheres to the guiding principle of serving economic development through technical intelligence. Upholding the motto of "comprehensive service concept, borderless information platform" and characterized by "authority, science, and rigor," it is dedicated to pharmaceutical information development and research, utilizing modern computer technology to actively build pharmaceutical information platforms. After over half a century of development, it has become one of the oldest, most authoritative, and technically strongest information centers in China's pharmaceutical industry system.
Core Content: The global API industry faces intensified international competition and supply chain decoupling challenges. India accelerates development through policy support, while China demonstrates advantages in stable supply, becoming the world's largest API exporter. Domestic policies promote high-quality development, increasing industry concentration, extending the industrial chain, adopting CDMO models, and expanding overseas markets. Enterprises must focus on core businesses, optimize product layouts, adapt to technological innovation and industry adjustments for sustainable development. This report analyzes the current domestic API industry's status, trends, and future prospects, emphasizing strategic focus and adaptation to international competition and policy changes through innovation, chain extension, and market expansion for high-quality growth.
Tang Wei
Senior Director of Analytical Sciences
HitGen Inc. (Stock code: 688222)
Speech Time: 14:10–14:40
Topic: "Development and Application of a Multidimensional Analytical System for New Molecular Drug R&D"
About the Speaker: Dr. Tang Wei graduated from Northwestern University under the mentorship of US National Academician Professor Richard B. Silverman, specializing in new drug mechanism research. Joined Eurofins (USA) in 2014 for R&D analysis, returned to China in 2017 to Zhejiang Jiuzhou Pharmaceutical for CMC R&D and compliance work, joined Pharmaron (Ningbo) in 2019 as Analysis Director, engaged in API R&D and quality control, and joined Chengdu Lead Drug in 2024 as Senior Director of Analytical Science, overseeing R&D analysis and quality control from hit compound discovery to IND filing stages.
About the Organization: Chengdu Lead Drug Development Co., Ltd. (688222.SH) is a leading innovative biopharmaceutical company headquartered in Chengdu with subsidiaries in Cambridge (UK) and Houston (USA). Focused on small molecule and nucleic acid drug discovery and optimization, it has established leading platforms including DNA-encoded compound library (DEL), fragment- and structure-based drug design (FBDD/SBDD), oligonucleotide drug development (OBT), and targeted protein degradation (TPD). The company is building a DEL+AI+automated DMTA (design-synthesis-testing-analysis) platform to accelerate preclinical candidate drug discovery and optimization. It collaborates with hundreds of pharmaceutical, biotech, chemical companies, foundations, and research institutions globally, with multiple internal drug projects in clinical and preclinical stages.
Yan Shengyong
Manager, Synthetic Method Development Department
JenKem Technology Beijing Inc. (Stock code: 688356)
Speech Time: 14:40–15:10
Topic: "Research on DBCO in Click Chemistry Technologies"
About the Speaker: Yan Shengyong holds a Ph.D. from Wuhan University, College of Chemistry and Molecular Sciences. He has published more than 10 SCI papers and has long been engaged in drug and excipient synthesis R&D, supporting industrial production of multiple drugs and excipients. He has led synthetic R&D for APIs in 5 new drug projects, all successfully scaled up. At Tianjin Jenkay Technology, he focused on PEG-drug conjugation, optimizing processes to scale production of high-purity ADC and PROTAC linkers.
About the Organization: Beijing Jenkay Technology Co., Ltd., established in October 2001, specializes in industrialization of medical and pharmaceutical polyethylene glycol derivatives. With a base over 15,000 m2 in Tianjin Biomedical Park and a high-purity PEG materials R&D and fully automated production line in Panjin, Liaoning, the company and subsidiaries are certified high-tech enterprises. It is one of the few domestic companies capable of large-scale industrial production of high-purity, low-dispersion medical PEG and active derivatives, pioneering and leading the market.
He Lianshun
Deputy Chief Engineer
Jingjing Pharmaceutical Co., Ltd. (Stock code: 835033)
Speech Time: 15:10–15:40
Topic: "Application of Immobilized Enzyme Catalysis in Amino Acid Biomanufacturing"
About the Speaker: He Lianshun, a CCP member and senior engineer born in November 1987, is a member of the China Inventors Association. Since joining the workforce in 2011, he has been dedicated to biomanufacturing, enzyme catalysis technology, and chemical crystallization technology. A key technical member at Jingjing Pharmaceutical, he leads enzyme catalysis and crystallization technology improvements, responsible for projects such as proline-glutamine, aspartic acid-ornithine, and calcium pantothenate. His leadership has enhanced product quality and market competitiveness, demonstrating industry-leading example.
About the Organization: Jingjing Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in R&D, production, and sales of high-quality APIs, intermediates, and amino acid series products. Holding 62 patents (39 invention patents), the company excels in customized capability, quality improvement, process innovation, and industry incubation. Utilizing strengths in biosynthesis (microbial fermentation, enzyme catalysis), chemical synthesis, and crystallization control, it offers high-value APIs and intermediates, establishing long-term strategic partnerships. It applies efficient enzyme catalysis industrially to amino acids and derivatives, achieving global leading cost and quality advantages.
Zhou Chundong
Senior Manager, Preparative Separation Department
Shanghai Haoyuan Pharmaceutical Co.,Ltd (Stock code: 688131)
Speech Time: 15:40–16:10
Topic: "Supporting New Drug Development through Preparative Liquid Chromatography Purification Technologies"
About the Speaker: Mr. Zhou Chundong has nearly 15 years of experience in small molecule drug analysis and separation, specializing in chiral drug analysis, preparative separation and resolution, and API/impurity purification. Formerly at WuXi AppTec, Hongbo Pharma, and Jichuan Pharma Shanghai Research Institute, he led the construction of chiral and impurity research labs and holds 6 invention patents. Currently at Shanghai Haoyuan Pharmaceutical, he leads SFC/normal phase analysis separation platform and overall lab operations, providing purification solutions for full drug development process.
About the Organization: Shanghai Haoyuan Pharmaceutical Co., Ltd., founded in 2006, focuses on R&D of life science reagents for small molecule and new molecular type drugs, API, intermediates, starting materials, formulations, process optimization, and commercial production. Innovation is core, with a "product + service" model targeting differentiated development. It offers integrated services covering starting materials, intermediates, APIs, and formulations, accelerating partner success from preclinical to commercial production. The company is a leading global supplier of research chemicals and biological reagents, and a trusted CRO & CDMO partner in intermediates, specialty APIs, and formulations.
Wang Yiyun
Deputy Director, Research Institute
Shandong Xinhua Pharmaceutical Co., Ltd. (Stock code: 000756)
Speech Time: 16:10–16:40
Topic: "From Batch to Continuous: Smart Manufacturing Leading a New Paradigm in Pharmaceutical Production"
About the Speaker: Wang Yiyun, male, Ph.D. candidate at Beijing Institute of Technology, senior engineer, core member of Taishan Industry Leading Talent Blue Talent Project, external master's advisor at BIT Graduate School of Chemistry and Chemical Engineering, graduate advisor at Southwest University, deputy chair of Zibo Medical Association's Clinical Pharmacy Research and Evaluation Branch, secretary of Zibo Pharmacy Society's Pharmaceutical Engineering Committee, member of Shandong Pharmacy Society's Pharmaceutical Engineering Committee, executive member of Shandong Pharmacy Society's Clinical Research Quality and Risk Management Committee. His work focuses on API R&D, production transformation, innovative drug development, biotechnology, and clinical research.
About the Organization: Shandong Xinhua Pharmaceutical Co., Ltd. is China's first chemical synthetic pharmaceutical company, a global major base for antipyretic and analgesic drugs, and a key producer of cardiovascular, anti-infective, nervous system, and steroid hormone drugs. It operates four major sectors: chemical APIs, formulations, intermediates, and e-commerce, with 5 industrial parks and 13 subsidiaries. Annual production includes 50,000 tons of chemical APIs, 500,000 tons of intermediates, 32 billion tablets, and 1.5 billion injections. The company holds leading market shares or exclusives in 26 products including aspirin, ibuprofen, levodopa, and others, with annual exports nearing $400 million and long-term partnerships with over 200 multinational companies such as Roche, Bayer, Merck, and Barr.
